Nevada
Provider Communications
Prior authorization requirements for injectable/infusible drugs: mepolizumab (Nucala) and reslizumab (Cinqair)
PA requirements will be added to the following:
- Mepolizumab (Nucala) — injection, 1 mg (J2182)
- Reslizumab (Cinqair) — injection, 1 mg (J2786)
To request PA, you may use one of the following methods:
- Web: https://www.availity.com
- Fax: 1-800-964-3627
- Phone: 1-844-396-2330
Not all PA requirements are listed here. PA requirements are available to contracted providers through the Availity Portal (https://www.availity.com). Providers who are unable to access Availity may call us at 1-844-396-2330.
ANV-NL-0032-18 August 2018
Featured In:
October 2018 Anthem Provider Newsletter - NV